Roy S Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital ; Associate Director for Translational Research, Yale Cancer Center; Disease Alligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center

Physician Biography

Dr. Herbst is a Professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.

Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.

Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Thoracic Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Lung Personalized Intervention Program: Tobacco treatment for patients at risk for lung cancer (PIP)
Lung Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer
Lung A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Cou
Lung A081105: Erlotinib Hydrochloride in Patients w/Stage IB-IIIA NSCLC That Has Been Removed Surgically
Lung E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been R
Lung A151216:Genetic Testing in Screening Patients w/Stage IB-IIIA NSCLC That Has Been or Will Be Removed
Lung Phase 3 study MPDL3290A with Cisplatin or Carboplatin+Pemetrexed for PD-L1- Stage 4 NSCLC
Lung Phase 3, MPDL3280A with Carboplatin+Paclitaxel or Carboplatin+Paclitaxel+Bevacizumab in NSCLC
Brain and Nervous System, Lung, Melanoma, skin Pembrolizumab and bevacizumab in untreated brain metastases
Lung Phase 3 - Nivo, or Nivo+Ipilmumab vs. platinum doublet chemo in chemotherapy-naive stage 4 or NSCLC
Lung Study Of PF-06463922 An ALK/ROS1 Inhibitor In Advanced NSCLC w/Specific Molecular Alterations
Lung Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent NSCLC
Lung CheckMate 331: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 331
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Lung, Phase I A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o

Edit this profile